We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CTCL

News List

Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients firstwordpharma
June 11, 2021
Kyowa Kirin today announced a new analysis of data showing statistically significant improvements in quality of life in cutaneous T-cell lymphoma (CTCL) patients treated with mogamulizumab with blood involvement, compared to vorinostat.
Kyowa Hakko Kirin announces results of Phase 3 trial of patients with Cutaneous T-cell Lymphoma biospectrumasia
August 14, 2018
MAVORIC study (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of mogamulizumab in patients with cutaneous T-cell lymphoma (CTCL) have been published in Lancet Oncology.
FDA Grants Breakthrough Therapy Designation for Mogamulizumab americanpharmaceuticalreview
August 28, 2017
Kyowa Hakko Kirin announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to their investigational product, mogamulizumab which is being developed for the treatment of Mycosis Fungoides (MF) and Sézary Syn